Generic Semaglutide in Canada: Pricing Guide and Cross-Border Notes for 2026
Canada is the first G7 country with two approved Ozempic generics: Dr. Reddy's Apr 28, Apotex May 1, Sandoz Q3 2026. Expected 45-90% cheaper than brand.
Health Canada approved two generic versions of semaglutide within five days. That makes Canada the first G7 country with more than one approved Ozempic generic. Dr. Reddy's Laboratories cleared on April 28, 2026. Apotex followed on May 1. Seven more submissions are still under Health Canada review. Sandoz has confirmed a Q3 2026 launch on its own filing.
Patent timing is the reason Canada moved first. Canadian patent protection on the key semaglutide molecules lapsed earlier than expected. The cause was a Novo Nordisk maintenance-fee issue. As a result, Canada runs roughly a year ahead of European patent expiry and five-plus years ahead of the US. For Canadian patients, this is the first real price relief. Generic prices are expected to run 45-90% below brand-name Ozempic and Wegovy.
For US patients, the direct benefit is limited. Importing drugs from Canada for personal use is legally constrained. But the Canadian market is a preview of what the US faces after December 2031, when key US patents expire. Watching how Canadian payers (insurers and government drug plans), prescribers, and patients adopt generic semaglutide gives the field a five-year window to plan for the same shift in the US.
This guide covers the approval timeline, expected generic pricing by manufacturer, payer coverage in Canada, cross-border purchase questions for US patients, and how Canadian patent timing compares with the rest of the world.
For full GLP-1 pricing context, see GLP-1 Pricing: May 2026. For US generic-semaglutide expectations, the December 2031 US patent cliff is the date to watch. Canada today previews that 2032-and-later market.
Health Canada approval timeline
Health Canada approved two generic semaglutide injections within five days. That made Canada the first G7 country with more than one approved Ozempic generic. Seven more submissions are in review. Health Canada moved quickly once Canadian patent protection lapsed.
| Channel | Price | Source |
|---|---|---|
| First Generic — Dr. Reddy's Laboratories | Approved April 28, 2026 | Health Canada |
| Second Generic — Apotex | Approved May 1, 2026 | Health Canada |
| Additional Submissions | 7 in Health Canada review | CBC News |
| Sandoz Generic Launch (Confirmed) | Q3 2026 commercial launch | Bloomberg |
Expected generic pricing in Canada (CAD)
Generic drugs in Canada typically cost 45-90% less than the brand under federal rules. Brand Ozempic retails for around CAD $300-400 per month in Canadian pharmacies (about USD $210-285). At a 45-90% discount, generics should land in the CAD $30-200 per month range. Each manufacturer sets its own final price, and it varies by pharmacy.
| Channel | Price | Source |
|---|---|---|
| Brand Ozempic Canada (Baseline) | CAD $300-400/mo (~$210-285 USD) | Walk In Virtual Clinic |
| Generic Semaglutide (Expected Mid-Range) | CAD $90-220/mo (~$65-155 USD) | Felix |
| Generic Semaglutide (Expected Low-End) | CAD $30-90/mo (~$22-65 USD) | OverTheBorderMeds |
| Provincial Drug Plan Coverage | Plan-by-plan | Benefits and Pensions Monitor |
Patent context — why Canada is first
Canada's semaglutide patent timing split from the rest of the G7 because of a Novo Nordisk maintenance-fee issue. The main patent on the molecule itself lapsed in Canada years before the matching patents in the US, EU, and UK. Data exclusivity, a separate period that blocks generics from relying on the brand's trial data, expired on January 4, 2026. That opened the regulatory path.
| Channel | Price | Source |
|---|---|---|
| Canadian Data Exclusivity Expiry | January 4, 2026 | Patent Lawyer Magazine |
| US Composition Patent | Expires December 2031 | Felix |
| EU Patent Expiry | Late 2026 - 2027 | Patent Lawyer Magazine |
| India Patent Expiry (Reference) | March 20, 2026 | Business Standard |
Cross-border considerations for US patients
Importing prescription drugs from Canada for personal use is a legal gray zone in the US. The FDA has historically let small personal-use quantities through customs. But the agency has signaled tighter enforcement against compounded GLP-1 supply chains, and enforcement on personal imports could tighten too. Patients considering Canadian generic semaglutide should talk to a US-licensed prescriber and a healthcare attorney before relying on it for ongoing therapy.
| Channel | Price | Source |
|---|---|---|
| Personal-Use Import (Up to 90-day Supply) | Legal gray zone | OverTheBorderMeds |
| Cold-Chain Logistics Cost | $50-150 per shipment | OverTheBorderMeds |
| US-Licensed Prescriber Required | Yes | Endor Health |
What this means for the US 2032 generic transition
The Canadian market is a five-year preview of the US semaglutide market after December 2031, when key US patents expire. How Canadian payers, generic makers, prescribers, and patients adapt to several competing generics is a live data set for planning the US transition. Three questions to track. How fast do Canadian payers move to generics as first-line coverage? Do brand Ozempic and Wegovy hold market share through prescriber loyalty and patient preference for a known molecule? And what happens to compounded GLP-1 supply once a $30-90 per month generic is on shelves?
| Channel | Price | Source |
|---|---|---|
| US Patent Cliff | December 2031 | Felix |
| Novo Nordisk 2027 WAC Cut (Announced) | ~$675/mo | Novo Nordisk PR |
| Tirzepatide Patent Expiry | 2036 | Coherent Market Insights |
Which Canadian provinces and pharmacy chains to watch
Generic semaglutide will roll out province by province. Each province's formulary committee decides when to list a generic and at what reimbursement level. (A formulary is the list of drugs a public or private plan pays for.) Ontario, British Columbia, and Quebec have historically moved fastest on generic uptake. Shoppers Drug Mart, Rexall, and London Drugs are the main pharmacy chains to watch. Loblaw's PC Optimum pharmacy network and Costco Canada also stock GLP-1s and will likely switch to generic supply once it is available.
| Channel | Price | Source |
|---|---|---|
| Ontario Drug Benefit Program | Pending formulary decision | CBC News |
| British Columbia PharmaCare | Pending formulary decision | Benefits and Pensions Monitor |
| Quebec RAMQ | Pending formulary decision | CBC News |
| Private Insurance (Group Plans) | Plan-by-plan | Benefits and Pensions Monitor |